
Upstream Bio Inc (UPB)
NASDAQ
The current UPB market cap is 310.04M. The company's latest EPS is USD -1.4242 and P/E is -4.30.
Quarter End | Sep 2024 | Dec 2024 | |
---|---|---|---|
USD ($) | USD ($) | USD ($) | |
Total Revenue | 607k | 613k | |
Operating Income | -18.89M | -26.32M | |
Net Income | -21.03M | -21.79M |
Year End December 30 2024 | 2022 | 2023 | 2024 |
---|---|---|---|
USD ($) | USD ($) | USD ($) | |
Total Revenue | 1.21M | 2.38M | 2.37M |
Operating Income | -23.91M | -40.11M | -77.76M |
Net Income | -23.87M | -38.26M | -76.4M |
Quarter End | Sep 2024 | Dec 2024 | |
---|---|---|---|
USD ($) | USD ($) | USD ($) | |
Total Assets | 232.7M | 481.72M | |
Total Liabilities | 393.01M | 11.87M | |
Total Equity | -160.31M | 469.85M |
Year End December 30 2024 | 2022 | 2023 | 2024 |
---|---|---|---|
USD ($) | USD ($) | USD ($) | |
Total Assets | 18.48M | 117.2M | 481.72M |
Total Liabilities | 124.63M | 240.32M | 11.87M |
Total Equity | -106.16M | -123.13M | 469.85M |
Quarter End | Sep 2024 | Dec 2024 | |
---|---|---|---|
USD ($) | USD ($) | USD ($) | |
Operating | -39.56M | -59.17M | |
Investing | -101.39M | -59.49M | |
Financing | 148.26M | 418.91M |
Year End December 30 2024 | 2022 | 2023 | 2024 |
---|---|---|---|
USD ($) | USD ($) | USD ($) | |
Operating | -19.02M | -37.93M | -59.17M |
Investing | -82k | -82.84M | -59.49M |
Financing | 9.96M | 129.55M | 418.91M |
Market Cap | 310.04M |
Price to Earnings Ratio | -4.30 |
Price to Sales Ratio | 138.46 |
Price to Cash Ratio | 1.01 |
Price to Book Ratio | 0.7 |
Dividend Yield | - |
Shares Outstanding | 53.64M |
Average Volume (1 week) | 243.46k |
Average Volume (1 Month) | 236.17k |
52 Week Change | -73.12% |
52 Week High | 29.30 |
52 Week Low | 5.515 |
Spread (Intraday) | 0.2 (3.42%) |
Company Name | Upstream Bio Inc |
Address |
251 little falls drive wilmington, delaware 19808 |
Website | https://www.upstreambio.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.